Peter J. Houghton PhD

Peter J. Houghton PhD
ProfessorCollege of MedicinePeter.Houghton@nationwidechildrens.org
Children's Hospital 700 Children's Drive Columbus OH 43205
Phone:614-355-2670Fax:
  • Experimental Therapeutics
  • Pediatric Oncology (Developing)
  • Administrative

Current Publications

  • Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MAInitial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Pediatr Blood Cancer 61 922-4 5/1/2014
  • Selvendiran KHO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer.Cancer Res 74 2316-27 4/15/2014
  • Blaney SMA phase I trial of MK-2206 in children with refractory malignancies: A children's oncology group study.Pediatr Blood Cancer 3/24/2014
  • Lock RBInitial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Pediatr Blood Cancer 3/24/2014
  • Studebaker AWTreatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.BMC Cancer 14 206 3/19/2014
  • Cam Hp53/TAp63 and AKT Regulate Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling through Two Independent Parallel Pathways in the Presence of DNA Damage.J Biol Chem 289 4083-94 2/14/2014
  • Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 158-64 1/1/2014
  • Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam H?Np63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis.Cancer Res 74 320-9 1/1/2014
  • Bid HK, Kibler A, Phelps D, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, Dewire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJDevelopment, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma.Clin Cancer Res 19 6716-29 12/15/2013
  • Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MAInitial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Pediatr Blood Cancer 60 1860-7 11/1/2013
  • Hsu SH, Wang B, Kutay H, Bid H, Shreve J, Zhang X, Costinean S, Bratasz A, Houghton P, Ghoshal KHepatic Loss of miR-122 Predisposes Mice to Hepatobiliary Cyst and HCC upon Diethylnitrosamine Exposure.Am J Pathol in press 10/7/2013
  • Bid HK, Roberts RD, Manchanda PK, Houghton PJRAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.Mol Cancer Ther 12(10) 1925-34 10/1/2013
  • Houghton PJNew insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?Expert Rev Anticancer Ther 13(10) 1135-8 10/1/2013
  • Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MAInitial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program.Pediatr Blood Cancer in press 9/9/2013
  • Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock RInitial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer in press 9/4/2013
  • Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.Pediatr Blood Cancer 60(8) 1325-32 8/1/2013
  • Yaseen Balkhi M, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DCmiR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.Sci Signal 6(286) ra63 7/30/2013
  • Shen C, Houghton PJThe mTOR pathway negatively controls ATM by up-regulating miRNAs.Proc Natl Acad Sci U S A 110(29) 11869-74 7/16/2013
  • Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60(7) E42-5 7/1/2013
  • Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJDual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.Clin Cancer Res 19(11) 2984-94 6/1/2013
  • Smith MA, Houghton PJA proposal regarding reporting of in vitro testing results.Clin Cancer Res 19(11) 2828-33 6/1/2013
  • Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJRegulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.Cancer Res 73(11) 3393-401 6/1/2013
  • Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MAInitial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.Pediatr Blood Cancer 60(5) 791-8 5/1/2013
  • Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of temozolomide by the pediatric preclinical testing program.Pediatr Blood Cancer 60(5) 783-90 5/1/2013
  • Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RBInitial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60(4) 633-41 4/1/2013
  • Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, Lock RBThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Clin Cancer Res 19(7) 1795-805 4/1/2013
  • Kaplon R, Hadziahmetovic M, Sommerfeld J, Bondra K, Lu L, Leasure J, Nguyen P, McHugh K, Li N, Chronowski C, Sebastian N, Singh M, Kurmasheva R, Houghton P, Pelloski CEThe application of radiation therapy to the Pediatric Preclinical Testing Program (PPTP): results of a pilot study in rhabdomyosarcoma.Pediatr Blood Cancer 60(3) 377-82 3/1/2013
  • Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MAInitial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.Pediatr Blood Cancer 59(7) 1266-74 12/15/2012
  • Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MAInitial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 59(4) 749-52 10/1/2012
  • Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJEvaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Pediatr Blood Cancer 59(4) 753-5 10/1/2012
  • Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MATesting of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59(3) 518-24 9/1/2012
  • Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MAInitial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59(3) 586-8 9/1/2012
  • Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VMA single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Invest New Drugs 30(4) 1660-70 8/1/2012
  • Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJInitial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer 59(2) 329-32 8/1/2012
  • Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJInitial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer 59(2) 329-32 8/1/2012
  • Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJInitial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.Pediatr Blood Cancer 59(2) 246-53 8/1/2012
  • Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MAInitial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 59(1) 185-8 7/15/2012
  • Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MAInitial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.Pediatr Blood Cancer 58(6) 916-23 6/1/2012
  • Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJCombination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.Pediatr Blood Cancer 58(5) 729-35 5/1/2012
  • Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MAInitial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.Pediatr Blood Cancer 58(5) 815-8 5/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu